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S222 Poster Session Itransplantation from an HLA-identical sibling or HLA-compatible
unrelated donor. All patients received a myeloablative regimen and
post-HSCT immunosuppression. Peripheral blood mononuclear
cell (PBMC) samples were collected fromdonors and from recipients
pre-transplant and at days 30, 60 and 200 post-transplant. Using
multiparameter flow cytometric analysis, we evaluated intracellular
IFN-g production among inhibitory KIR-expressing NK subsets
following activation with the class I-deficient 721.221 target cell
line or with 721.221 transfectants expressing the KIR ligands HLA
-Cw3, -Cw4, or -Bw4. Unlicensed NK cells expressing inhibitory
KIR for non-self HLA were hyporesponsive in normal donors. In
comparison, the same NK subsets in patients early post-HCT
(days 15-60) demonstrated robust IFN-g production to target cells
lacking cognate class I ligand (p\0.001). As for TCD HCT, the
temporary licensing effect of nonself-specific NK cells following
T-replete HCT lasted for approximately 100 days, after which NK
cells expressing KIR for non-self HLA returned to a hyporesponsive
state. NK cells expressing inhibitory KIR for self-HLA remained un-
changed in their responsiveness pre- and post-HCT. These findings
contrasted with our previous results in recipients of T-cell depleted
grafts where both licensed and unlicensedNK cells demonstrated in-
creased functional activity early post SCT. KIR expression was gen-
erally delayed following T-replete HCT, with KIR2DL1
particularly lagging in expression beyond 100 days post-HCT.
These results demonstrate that T-cells in the HCT allograft do
not interfere with the temporary licensing effects on NK cells ex-
pressing inhibitory KIR for non-self HLA, which mediate NK allor-
eactivity in HLA-matched HCT.174
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Background: IR in pediatric transplant recipients appears to take
longer following MAC and UCBT than following matched sib-
ling allogeneic stem cell transplantation (AlloSCT) (Parkman et
al., BBMT, 2006). While RTC prior to AlloSCT is associated
with decreased transplant-related morbidity and mortality com-
pared with MAC, effects of RTC on long-term IR in pediatric
UCBT recipients are unknown (Satwani, Cairo et al., BBMT,
2005).
Objective: To determine the probability of IR following UCBT in
pediatric recipients and risk factors associated with recovery.
Methods: IRwas evaluated in 88 consecutive pediatricUCBT recip-
ients at days +100, +180 and +365. Absolute lymphocyte subsets and
Ig levels were assessed using FACS analysis and ELISA and charac-
terized as normal or low by age-specific norms (Table 1).
Results: 88 pts: median age 6.5 yrs (range 0.25-22); 59% male/41%
female; 56%MAC/44%RTC;HLAmatch 19% 6/6, 28% 5/6, 52%
4/6; 66%malignant/34%non-malignant;medianTNCx107/kg 3.81
(0.9-22.61),medianCD34 x105/kg 2.13 (0.34-9.57).Day 180NKcell
levels were slightly higher in theMAC vs. RTC group (p5 .05); oth-
erwise, lymphocyte subsets and immunoglobulin levels did not differ
significantly between MAC and RTC groups but were similarly de-
layed with respect to CD3, CD4 and CD8. Grade II-IV aGVHD,
ATG/Campath conditioning, viral/fungal infection and TNC/
CD34 dose/kg were not associated withT, B andNK cell reconstitu-
tion.
In 79 evaluable pts, the Kaplan-Meier probability of grade II-IV
aGVHDwas 33.8% (CI95 23.8%-46.5%). In aCox proportional haz-
ards model that included conditioning regimen (MAC vs. RTC), risk(average vs. poor),HLA-matching (4/6 vs. 5-6/6),CMVstatus (donor
neg/recipient neg vs. other) and time period (before 2005 vs. 12/31/
04 onward) to analyze predictors of grade II-IV aGVHD, MAC re-
cipients had a significantly higher risk of grade II-IV aGVHD (HR
5.0, CI95 1.8-14.1, p5 .002) along with those receiving a 4/6 HLA-
matched cord blood unit (HR 3.0, CI95 1.2-7.8, p5 .02). In a similar
Cox model, pts receiving a 4/6 cord blood graft had a significantly
higher risk of chronic GVHD (HR 30.7, CI95 2.2-433.1, p5 .01).
Conclusions: B and NK cell IR were both fairly robust following
UCBT in pediatric pts regardless of conditioning intensity. How-
ever, T cell IR was delayed but unaffected by RTC. Although
RTC was associated with significantly less Grade II-IV aGVHD,
new methods are needed in the future to accelerate T cell IR post-
UCBT.
Table 1. Absolute lymphocyte subset counts and immuno-
globulin levels and percentages of children achieving normal
counts post-UCBT, stratified by conditioning regimen
MAC RTC TotalSubset/
Level,
Date Post-
TransplantMean6 SD
(cells/mL
or mg/dL) N%
ormalMean6 SD
(cells/mL
or mg/dL) N%
ormalMean6 SD
(cells/mL
or mg/dL) N%
ormalCD3 Day
100207.96 232.6 0 261.76 251.1 0 238.26 240.8 0CD3 Day
180425.16 344.5 0 378.56 390.0 0 396.36 365.1 0CD3 Day 3651809.16 1392.9 50 1541.46 1141.1 56 1630.66 1206.8 54CD4 Day
100101.16 83.8 0 136.36 176.5 0 120.96 142.6 0CD4 Day
180271.56 213.7 25 211.26 259.3 8 234.16 239.2 14CD4 Day
365770.16 628.7 50 933.26 597.7 81 878.86 599.6 71CD8 Day
10090.76 180.0 7 101.66 118.3 0 96.86 145.9 3CD8 Day
180137.96 167.1 13 135.56 109.9 0 136.46 130.5 5CD8 Day
365935.66 932.6 50 563.56 426.1 63 687.56 644.4 58CD19 Day
100525.26 571.1 43 649.36 577.8 61 595.06 569.0 53CD19 Day
180
1057.66 678.2 63 778.06 804.8 69 884.56 754.3 67CD19 Day
365916.06 621.7 75 1170.36 585.8 100 1085.56 597.0 92CD56 Day
100255.06 174.0 71 249.46 169.0 83 251.86 168.4 78CD56 Day
180310.06 212.5 75 171.36 83.1 69 224.16 157.2 71CD56 Day
365369.36 178.1 86 255.16 153.0 81 289.86 165.8 83IgG Day
100642.56 278.3 62 649.66 210.5 50 647.06 233.9 54IgG Day
180672.66 367.1 40 623.86 258.1 50 648.26 309.8 45IgG Day
365606.16 298.6 50 728.76 178.8 70 674.26 240.0 61IgM Day
10031.06 26.5 31 30.86 21.1 45 30.96 22.8 40IgM Day
18056.36 45.2 70 57.76 47.4 70 57.06 45.1 70IgM Day
36589.16 43.5 88 88.86 72.6 90 88.96 59.7 89IgA Day
10041.66 51.3 62 124.66 249.9 64 93.76 237.3 63IgA Day
18060.36 64.8 80 61.26 50.0 60 60.86 56.3 70IgA Day
36587.36 84.2 75 77.16 47.9 80 81.66 64.5 78
